What's Happening?
Parse Biosciences has announced the inclusion of Tempus in its Certified Service Provider (CSP) Program, aimed at expanding access to scalable single cell sequencing technologies. This collaboration seeks to integrate Tempus' multi-omics expertise with Parse's advanced single cell platform, enhancing the ability to conduct large-scale, data-driven studies. The CSP Program, launched in 2024, connects premier service providers globally, facilitating straightforward access to advanced single cell technologies. Tempus, through this partnership, aims to offer reliable solutions for research, leveraging Parse's scalability and quality.
Why It's Important?
The collaboration between Parse Biosciences and Tempus is significant for the advancement of multi-omics research, particularly in fields like cancer treatment, tissue repair, and stem cell therapy. By combining Parse's scalable single cell sequencing technology with Tempus' data-driven expertise, researchers can tackle complex biological questions more effectively. This partnership is poised to drive breakthroughs in scientific research, offering a reliable path from exploratory research to comprehensive studies, thereby accelerating advancements in human health.
What's Next?
As Parse Biosciences and Tempus work together, the focus will be on delivering integrated data solutions to tackle complex biological questions. The partnership is expected to enhance the capabilities of researchers in conducting large-scale studies, potentially leading to significant advancements in various life sciences fields. The expansion of Parse's CSP Program and the inauguration of its new facility in Seattle will further support these efforts, providing state-of-the-art resources for global research initiatives.
